← Research library

Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9

Patent disclosure · 2023

What the patent describes
Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.
Reported evidence
The patent describes the NT-3 mimetic series underlying GTS-301 and GTS-302. Patent examples may overlap with later publications and are not independent clinical evidence.

Composite withdrawal index · Reported reductions of 26.9%, 41.4% and 36.5% across three tested exposures · Relative to active control; nonmonotonic dose pattern retained

Reported patent results

Reported findings

GTS-302 reduced the composite withdrawal index while several individual signs and general activity remained unchanged.

Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.

Population or model Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.

Results · Final withdrawal-model example; composite-index and unchanged-sign narrative.
MeasureResultComparison, timing and statistics
Composite withdrawal indexReported reductions of 26.9%, 41.4% and 36.5% across three tested exposuresRelative to active control; nonmonotonic dose pattern retained
Neutral signsNo significant changes in general motor activity, rearing, grooming or several listed withdrawal signsNot every component improved

Animal withdrawal scores do not establish treatment of human dependence. Values are specific to GTS-302 and cannot be assigned to all NT-3 mimetics.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Molecule. Corrected publication describing dimeric NT-3 peptide mimetics; proposed disease indications are not demonstrated human efficacy.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2800369C9 ↗ · 2023-10-04
Earliest priority / filing
Not established / 2022-04-05
Original applicant / assignee
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications

Dimeric dipeptide mimetics of neurotrofin-3

Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Юлия Венеровна Вахитова; Полина Юрьевна Поварнина; Татьяна Алексеевна Антипова; Лариса Геннадьевна Колик; Нелля Михайловна Сазонова; Алексей Валерьевич Тарасюк; Дмитрий Михайлович Никифоров; Лиана Фанзилевна Зайнуллина; Марк Анатольевич Константинопольский; Светлана Сергеевна Ягубова; Рита Ушеровна Островская; Сергей Владимирович Николаев; Илья Олегович Логвинов.

RU2800369C9

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Patent claims are not evidence of approved clinical uses.
  • Some publications describe shared experiments or have corrections.

Source details

Selected original-source text checked; full methodological review pending.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsRussian-language source

Author unconfirmed. Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9 Primary source linked above

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards